Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CA 2978286 C · Owner: Intrexon Corporation · Inventors: Cress, Dean Ervin; Palli, Subba Reddy; Fujimoto, Ted Tsutomu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to the field of biotechnology or genetic engineering. Specifically this invention relates to the field of gene expression. More specifically this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy large scale production of proteins and antibodies cell-based high throughput screening assays functional genomics and regulation of traits in transgenic organisms.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 20, 2002 and granted February 25, 2020. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.